Back to Agenda
[V2-S4] For the Success of the Global/Asia MRCT
Session Chair(s)
Eri Sekine
Executive Vice President
CMIC Group, Japan
Globalization of drug development progresses, and cases in which Japan leads clinical trials in the Asia region, and/or participates upon request in multi-regional clinical trials (MRCTs) from early stage of clinical development, are increasing. On the other hand, we have often seen confusion in globalization or MRCTs due to not only language barriers, but also different cultures, medical environments, and regulations between Japan and other regions. To demonstrate Japanese leadership globally, we must build up more experience in these areas. Presenters experienced in MRCTs from the global and Asian perspectives, from various pharmaceutical companies, will introduce the challenges and efforts of successful MRCTs, and how Japan can demonstrate the knowledge, the skills, and mindset necessary to lead global drug development.
Speaker(s)
To Maximize Japan/Asia Presence in P3 MRCT
Kazutaka Suga, PhD
Astellas Pharma Inc., Japan
Senior Manager, Japan/Asia Clinical Development 1, Development
Rebuild of Strategic Collaboration with Global CRO for Successful MRCT
Nobuhiro Koga, MBA, PMP
Nihon Servier Co., Ltd., Japan
Director, Clinical Operation
Expectation and Role of Japan in Global Drug Development Based on Experience of MRCT for Last 10 Years
Fuminori Shindoh
Chugai Pharmaceutical Co., Ltd., Japan
Group Manager, Translational Clinical Research Division
Joining Global First-in-Human Studies in Oncology Drug Development
Hideyasu Ishibashi, PhD
Novartis Pharma K.K., Japan
Head, Translational Clinical Oncology
Have an account?